In high-risk recurrent prostate cancer, overall survival did not differ significantly between leuprolide alone and enzalutamide monotherapy (P = 0.19).
In plain wordsIn patients with high-risk recurrent prostate cancer, overall survival did not differ significantly between leuprolide alone and enzalutamide monotherapy.
- Peptide
- Leuprolide
- Outcome
- No significant changeOverall survival
- Study
n: not reported in source
- Comparator
- Enzalutamide monotherapy
- Analysis
- Secondary
- Outcome group
- Mortality · Cancer
- Studied dose
- Dose not stated
Measurements
- 8-year survival
- 69.5%
- leuprolide alone
- 95% CI lower
- 64%
- leuprolide alone survival
- 95% CI upper
- 74.3%
- leuprolide alone survival
- 8-year survival
- 73.1%
- enzalutamide monotherapy
- 95% CI lower
- 67.6%
- monotherapy survival
- 95% CI upper
- 77.9%
- monotherapy survival
- Hazard ratio
- 0.83
- monotherapy versus leuprolide
- 95% CI lower
- 0.63
- hazard ratio
2 more measurements in the study.
Source sentences
The 8-year overall survival with monotherapy was 73.1% (95% CI, 67.6 to 77.9), which did not differ significantly from that with leuprolide alone (hazard ratio, 0.83; 95% CI, 0.63 to 1.10; P = 0.19).
3 context sentences(design, population, supporting numbers)
and 69.5% (95% CI, 64.0 to 74.3) in the leuprolide-alone group
Overall survival was an alpha-controlled, key secondary end point.
We randomly assigned patients with prostate cancer who had high-risk biochemical recurrence in a 1:1:1 ratio to receive enzalutamide plus leuprolide (the combination group), leuprolide alone (the leuprolide-alone group), or enzalutamide monotherapy (the monotherapy group).